SouthState Corp’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.47M Sell
40,126
-6,887
-15% -$326K 0.07% 169
2025
Q4
$2.39M Sell
47,013
-801
-2% -$41K 0.11% 136
2025
Q3
$2.65M Sell
47,814
-2,800
-6% -$164K 0.12% 126
2025
Q2
$3.49M Buy
50,614
+628
+1% +$42.7K 0.15% 114
2025
Q1
$3.47M Buy
49,986
+735
+1% +$60.7K 0.16% 112
2024
Q4
$4.24M Sell
49,251
-1,474
-3% -$159K 0.28% 84
2024
Q3
$6.04M Sell
50,725
-6,842
-12% -$912K 0.42% 59
2024
Q2
$8.22M Sell
57,567
-1,824
-3% -$242K 0.6% 48
2024
Q1
$7.63M Buy
59,391
+6,473
+12% +$771K 0.59% 51
2023
Q4
$5.47M Sell
52,918
-1,524
-3% -$151K 0.47% 58
2023
Q3
$4.95M Buy
54,442
+1,370
+3% +$121K 0.47% 55
2023
Q2
$4.29M Buy
53,072
+844
+2% +$68.9K 0.38% 65
2023
Q1
$4.16M Sell
52,228
-7,716
-13% -$547K 0.38% 72
2022
Q4
$4.06M Sell
59,944
-3,288
-5% -$193K 0.38% 71
2022
Q3
$3.15M Buy
63,232
+1,244
+2% +$66.6K 0.31% 75
2022
Q2
$3.45M Sell
61,988
-1,174
-2% -$65.1K 0.32% 76
2022
Q1
$3.51M Buy
63,162
+8,266
+15% +$424K 0.28% 84
2021
Q4
$3.08M Sell
54,896
-1,154
-2% -$62.5K 0.24% 94
2021
Q3
$2.69M Sell
56,050
-920
-2% -$44.5K 0.23% 97
2021
Q2
$2.39M Sell
56,970
-4,156
-7% -$161K 0.21% 99
2021
Q1
$2.06M Sell
61,126
-1,780
-3% -$63.4K 0.19% 102
2020
Q4
$2.2M Sell
62,906
-1,494
-2% -$51.6K 0.22% 95
2020
Q3
$2.23M Sell
64,400
-730
-1% -$24.3K 0.23% 92
2020
Q2
$2.13M Sell
65,130
-300
-0.5% -$9.57K 0.26% 86
2020
Q1
$1.97M Sell
65,430
-11,480
-15% -$342K 0.29% 81
2019
Q4
$2.23M Sell
76,910
-2,780
-3% -$77K 0.26% 93
2019
Q3
$2.06M Sell
79,690
-15,290
-16% -$387K 0.26% 93
2019
Q2
$2.42M Sell
94,980
-11,490
-11% -$284K 0.28% 92
2019
Q1
$2.78M Sell
106,470
-600
-0.6% -$14.7K 0.29% 90
2018
Q4
$2.47M Hold
107,070
0.28% 95
2018
Q3
$2.52M Sell
107,070
-1,594
-1% -$38.9K 0.26% 102
2018
Q2
$2.51M Sell
108,664
-866
-0.8% -$20.6K 0.28% 96
2018
Q1
$2.7M Sell
109,530
-1,530
-1% -$40.2K 0.31% 91
2017
Q4
$2.98M Buy
111,060
+5,662
+5% +$144K 0.32% 87
2017
Q3
$2.54K Sell
105,398
-300
-0.3% -$6.78K 0.28% 91
2017
Q2
$2.27M Sell
105,698
-840
-0.8% -$16.9K 0.29% 91
2017
Q1
$1.83M Sell
106,538
-4,544
-4% -$79.1K 0.24% 104
2016
Q4
$1.99M Sell
111,082
-2,260
-2% -$41K 0.29% 95
2016
Q3
$2.36M Buy
113,342
+4,640
+4% +$115K 0.36% 83
2016
Q2
$2.92M Sell
108,702
-9,278
-8% -$254K 0.44% 79
2016
Q1
$3.2M Sell
117,980
-4,100
-3% -$110K 0.5% 73
2015
Q4
$3.54M Sell
122,080
-3,700
-3% -$102K 0.56% 68
2015
Q3
$3.41M Sell
125,780
-1,160
-0.9% -$32.8K 0.52% 72
2015
Q2
$3.48M Sell
126,940
-7,534
-6% -$212K 0.48% 72
2015
Q1
$3.59M Sell
134,474
-67,048
-33% -$1.54M 0.51% 66
2014
Q4
$4.26M Buy
201,522
+22,684
+13% +$507K 0.67% 51
2014
Q3
$4.26M Buy
178,838
+14,416
+9% +$332K 0.65% 55
2014
Q2
$3.8M Buy
164,422
+10,432
+7% +$230K 0.63% 59
2014
Q1
$3.51M Buy
153,990
+28,500
+23% +$607K 0.57% 65
2013
Q4
$2.32M Buy
125,490
+9,050
+8% +$158K 0.38% 84
2013
Q3
$1.97M Buy
116,440
+20,720
+22% +$348K 0.37% 88
2013
Q2
$1.48M Buy
+95,720
New +$1.59M 0.31% 89

Other funds holding NVO

SouthState Corp's NVO Position: Q1 2026 in Review

SouthState Corp reduced its Novo Nordisk (NVO) stake by 15% in Q1 2026, selling an estimated $326K and leaving 40,126 shares worth $1.47M. The position accounts for 0.07% of the portfolio, ranked #169.

SouthState Corp first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.22M in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • SouthState Corp held 40,126 shares of Novo Nordisk worth $1.47M as of Q1 2026.
  • SouthState Corp sold 6,887 Novo Nordisk shares in Q1 2026, an estimated $326K.
  • Novo Nordisk made up 0.07% of SouthState Corp's portfolio in Q1 2026, its #169 holding.
  • SouthState Corp first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
  • SouthState Corp's Novo Nordisk position peaked at $8.22M in Q2 2024.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on SouthState Corp's 13F filing for Q1 2026, filed 5 May 2026.